APCCC 2019 PRESENTATION SLIDES

Get Free Access to Session Slides

APCCC 2019 VL

The Aging Population: Oncogeriatric Assessment and Treatment Considerations Presentation - Joe O'Sullivan

Details
Joe O'Sullivan presented on the aging population and how to properly assess them in the context of prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The age at diagnosis of prostate cancer has been increasing over time, while prostate cancer mortality has been decreasing. Aging is associated with increased comorbidities, which may affect the tolerance of therapies...

The Management of Hot Flushes in Advanced Prostate Cancer - Mark Frydenberg

Details
In this presentation, Mark Frydenberg presents the topic of hot flushes caused by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Hot flushes are defined as a subjective feeling of warmth in the upper torso, followed by excessive perspiration. Dr. Frydenberg focuses on the various treatment options for hot flushes, including medical treatments...

The Management of Sexuality and Incontinence in Advanced Prostate Cancer Presentation - Inge Van Oort

Details
Inge van Oort presented the topic of managing sexuality and incontinence issues in patients with advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). When assessing sexual symptoms she references the EAU guidelines on sexual activity and the percentage of prostate cancer patients that will receive androgen deprivation therapy (ADT) at some point in the diseas...

A Subgroup Analysis of mCRPC Clinical Trials Presentation - Susan Halabi

Details
In this presentation, Susan Halabi discusses the implications of subgroup analyses in metastatic castration-resistant prostate cancer (mCRPC) trials during the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The challenge, according to Dr. Halabi, is balancing the dichotomy of the danger of interpreting subgroup analysis with applying overall results o...

First - Line mCRPC After ADT + Docetaxel or AR Pathway Inhibitor Presentation - Mary-Ellen Taplin

Details
Mary-Ellen Taplin presents on the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel or AR pathway inhibitors in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. There are currently no prospective clinical trial data to guide the optimal selection of treatment for first-line mCRPC after ADT/docetaxel or ADT/AR-inhibition. Dr. Taplin exp...

The Treatment of Non-Metastatic Castration-Resistant Prostate Cancer: "Pros" Presentation - Maha Hussain

Details
Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...

The "Cons" of Treating nmCRPC - Important Considerations to Take into Account Presentation - Celestia Higano

Details
Celestia (Tia) Higano followed Maha Hussain's presentation on the "pros" of the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with the opposing side of the debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Higano focuses on the "cons" of treating men with nmCRPC and highlights an extensively covered topic at the meeting, the emergence and upd...

The Future of Advanced Prostate Cancer Management: In Locally Advanced Prostate Cancer Presentation - Alberto Briganti

Details
At the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Alberto Briganti shares his thoughts on where he would like to see the treatment of locally advanced prostate cancer in the future. Dr. Briganti's presentation covers 4 major areas where he views opportunity for progress: the intensification of tailored multi-modal approaches, image-guided surgery, the use of novel tools to improve...

Radium-223 and Bone Health Agents: Lessons Learned Presentation - Oliver Sartor

Details
Oliver Sartor presented the impact and use of radium-223 during the Bone and Bone Metastases Session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Sartor explains how Radium-223 first gained prominence with the reporting of the ALSYMPCA trial in 2013 which led to the FDA approval of radium-223 in the United States for patients with bone mCRPC without visceral metastases hi...

The Best Use of Antiresorptive Therapy in CRPC Presentation - Matthew Smith

Details
Matthew Smith presented a summary detailing the best use of osteoclast-targeted therapy for patients with bone metastatic castration-resistant prostate cancer (mCRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Emphasizing the importance to distinguish between skeletal-related events and fragility fractures secondary to osteoporosis, Dr. Smith covers the current landscape fo...
email news signup